Si12-C10 is a siloxane-incorporated lipid for spleen-targeting mRNA delivery. The siloxane moieties enhance cellular internalization of mRNA-LNPs and improve their endosomal escape capacity, augmenting their mRNA delivery efficacy.

JNJ-74856665 is an orally bioavailable, potent, and selective DHODH inhibitor with IC50 of 0.40 nM. JNJ-74856665 shows favorable physicochemical properties and has been selected for clinical development in patients with AML and myelodysplastic syndromes (MDS).

JAB-3312 is a potent SHP2 allosteric inhibitor with binding Kd of 0.37 nM, enzymatic IC50 of 1.9 nM, KYSE-520 antiproliferative IC50 of 7.4 nM and p-ERK inhibitory IC50 of 0.23 nM, respectively.

EDP-235 is a SARS-CoV-2 3CLpro inhibitor with potent nanomolar activity against all SARS-CoV-2 variants, as well as clinically relevant human and zoonotic coronaviruses. EDP-235 maintains potency against variants bearing mutations associated with nirmatrelvir resistance. EDP-235 demonstrates a ≥ 500-fold selectivity index against multiple host proteases.

BI-9787 is a potent zwitterionic ketohexokinase inhibitor with nanomolar activity against hKHK-C, hKHK-A, mKHK-C and rKHK-C. BI-9787 shows >100-fold selectivity for all targets except PDE4D2.

YD23 is a potent and highly selective degrader of SMARCA2. YD23 has potent tumor growth inhibitory activity in SMARCA4-mutant xenografts.